Fructose-1,6-bisphosphate reduces the mortality in Candida albicans bloodstream infection and prevents the septic-induced platelet decrease.

Roberto Christ Vianna Santos, Rafael Noal Moresco, Miguel Angel Peña Rico, Antonio R García Susperregui, Jose Luis Rosa, Ramon Bartrons, Francesc Ventura, Débora Nunes Mário, Sydney Hartz Alves, Etiane Tatsch, Helena Kober, Ricardo Obalski de Mello, Patrícia Scherer, Henrique Bregolin Dias, Jarbas Rodrigues de Oliveira

Index: Inflammation 35(4) , 1256-61, (2012)

Full Text: HTML

Abstract

Due to the fact that an increased number of patients have experienced bloodstream infections caused by Candida species and the high mortality of this infection, there is a need for a strategy to reduce this scenery. One possible strategy is the use of new drugs, such as fructose-1,6-bisphosphate (FBP), which is a high-energy glycolytic metabolite and has shown to have therapeutic effects in several pathological conditions such as ischemia, shock, toxic injuries, and bacterial sepsis. The aim of this manuscript was to determine the role of FBP in experimental Candida albicans bloodstream infection. We used mice that were divided into three experimental groups: sham (not induced), bloodstream infection (induced with intratracheal instillation of C. albicans) and FBP (bloodstream infection plus FBP 500 mg/kg i.p.). Blood was taken for assessment of complete hematological profile and cytokine assay (IL-6 and MCP-1). Results of the study demonstrated that mortality decreased significantly in groups that received FBP. All cytokine and hematological indexes of FBP group were similar to bloodstream infection group with exception of platelets count. FBP significantly prevented the decrease in platelets. Taken together, our results demonstrate that FBP prevented the mortality in C. albicans bloodstream infection.